Commack, NEW%20YORK10 Active Studies

Lung Cancer Clinical Trials in Commack, NEW%20YORK

Find 10 actively recruiting lung cancer clinical trials in Commack, NEW%20YORK. Connect with local research sites and explore new treatment options.

10
Active Trials
2
Sponsors
1,275
Enrolling

Recruiting Lung Cancer Studies in Commack

RecruitingCommack, NEW%20YORKNCT04410796

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change...

571 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT05967689

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring...

224 participants
Taiho Oncology, Inc.
View Study Details
RecruitingCommack, NEW%20YORKNCT05429320

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung ...

90 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT01639508

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or incre...

86 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT05657873

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-sm...

68 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT04991025

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in sh...

60 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT06007937

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug co...

56 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT06741085

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

The researchers are doing this study is to find out whether treating brain metastasis with SRS after 3 months of therapy with osimertinib is better than treating with osimertinib alone in people with ...

56 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT06582771

A Study of Sotorasib in People with Non-Small Cell Lung Cancer

The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received t...

39 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingCommack, NEW%20YORKNCT05607108

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug c...

25 participants
Memorial Sloan Kettering Cancer Center
View Study Details

About Lung Cancer Clinical Trials in Commack

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 10 lung cancer clinical trials recruiting participants in Commack, NEW%20YORK. These studies are seeking a combined 1,275 participants. Research is being sponsored by Memorial Sloan Kettering Cancer Center, Taiho Oncology, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Commack — FAQ

Are there lung cancer clinical trials in Commack?

Yes, there are 10 lung cancer clinical trials currently recruiting in Commack, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Commack?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Commack research site will contact you about next steps.

Are clinical trials in Commack free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Commack studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 10 active trials in Commack are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated March 2, 2026 from ClinicalTrials.gov